BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 14570730)

  • 21. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
    Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
    Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
    Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
    J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer.
    Gu J; Yamamoto H; Fukunaga H; Danno K; Takemasa I; Ikeda M; Tatsumi M; Sekimoto M; Hatazawa J; Nishimura T; Monden M
    Dig Dis Sci; 2006 Dec; 51(12):2198-205. PubMed ID: 17080242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
    Smyczek-Gargya B; Fersis N; Dittmann H; Vogel U; Reischl G; Machulla HJ; Wallwiener D; Bares R; Dohmen BM
    Eur J Nucl Med Mol Imaging; 2004 May; 31(5):720-4. PubMed ID: 14991243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.
    Contractor KB; Kenny LM; Stebbing J; Challapalli A; Al-Nahhas A; Palmieri C; Shousha S; Lewis JS; Hogben K; De Nguyen Q; Coombes RC; Aboagye EO
    Nucl Med Commun; 2011 Nov; 32(11):997-1004. PubMed ID: 21862943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
    Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
    Yamane T; Takaoka A; Kita M; Imai Y; Senda M
    Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidental focal uptake in colorectal location on oncologic ¹⁸FDG PET and PET/CT studies: histopathological findings and clinical significances.
    Fuertes J; Montagut C; Bullich S; Coma MI; Mestre-Fusco A; Suárez-Piñera M; Trampal C; Bellmunt J
    Rev Esp Med Nucl Imagen Mol; 2015; 34(2):95-101. PubMed ID: 25263718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.
    Buck AK; Schirrmeister H; Hetzel M; Von Der Heide M; Halter G; Glatting G; Mattfeldt T; Liewald F; Reske SN; Neumaier B
    Cancer Res; 2002 Jun; 62(12):3331-4. PubMed ID: 12067968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2.
    Jiang H; Guo W; Huang K; Jiang H; Zhang R; Hu H; Lin X; Wang S
    Abdom Radiol (NY); 2021 Jul; 46(7):3227-3237. PubMed ID: 33712897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study for texture analysis of
    Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Kitazono M; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2158-2168. PubMed ID: 28770274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical relevance of imaging proliferative activity in lung nodules.
    Buck AK; Hetzel M; Schirrmeister H; Halter G; Möller P; Kratochwil C; Wahl A; Glatting G; Mottaghy FM; Mattfeldt T; Neumaier B; Reske SN
    Eur J Nucl Med Mol Imaging; 2005 May; 32(5):525-33. PubMed ID: 15599526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases.
    Riedl CC; Akhurst T; Larson S; Stanziale SF; Tuorto S; Bhargava A; Hricak H; Klimstra D; Fong Y
    J Nucl Med; 2007 May; 48(5):771-5. PubMed ID: 17475966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
    Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
    Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
    Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
    J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer.
    Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF
    Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.